The entire study «Use of Lenalidomide in 5q - Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis» can be viewed in the August issue of CHEST. (sciencedaily.com)
While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival. (sciencedaily.com)
At seven years, 62 % of those treated with maintenance lenalidomide had survived, compared to 50 % of those in the control group. (sciencedaily.com)